Flaxseed Alone or in Combination with Tamoxifen Inhibits MCF-7 Breast Tumor Growth in Ovariectomized Athymic Mice with High Circulating Levels of Estrogen
Restricted accessOtherFirst published online September, 2007
Flaxseed Alone or in Combination with Tamoxifen Inhibits MCF-7 Breast Tumor Growth in Ovariectomized Athymic Mice with High Circulating Levels of Estrogen
Flaxseed (FS) is rich in mammalian lignan precursors and α-linolenic acid, which have been suggested as having anticancer effects. Previous studies have shown that 10% FS inhibits the growth of human estrogen–dependent breast cancer (MCF-7) in athymic mice, and it enhances the inhibitory effect of tamoxifen (TAM). This study determined whether the effect of FS, alone or in combination with TAM, is dose dependent, and it explored the potential mechanism of action. Ovariectomized athymic mice with estradiol (E2) supplementation (1.7 mg/pellet, 60-day release) and established MCF-7 tumors were treated with basal diet control (0FS), 5% FS (5FS), 10% FS (10FS), and TAM (TAM/ 0FS; 5 mg/pellet, 60-day release), alone or in combination (TAM/ 5FS and TAM/10FS) for 8 weeks. Compared with control, 5FS and 10FS significantly inhibited tumor growth by 26% and 38%, respectively. TAM/0FS had an effect similar to the 10FS. TAM/ 5FS and TAM/10FS, respectively, induced significant 48% and 43% reductions in tumor size compared with 0FS, and 18% and 10% reductions compared with TAM/0FS. The relative uterine weight was significantly lower in all TAM groups compared with the control. The reduction of tumor growth resulted from decreased cell proliferation and increased cell apoptosis. TAM/ 5FS caused a significantly higher expression of estrogen receptor-α (ERα) compared with 5FS and TAM/0FS, whereas TAM/10FS had a higher ERα than 10FS and TAM/0FS. Compared with the control, progesterone receptor (PgR) expression was significantly reduced in all treatment groups, but insulin-like growth factor-1 (IGF-1) expression was reduced only by 10FS, TAM/5FS and TAM/10FS. Tumor cell proliferation was significantly positively associated with expression of PgR and IGF-1 and negatively associated with apoptosis and ERα. Apoptosis was only associated with ERα. In conclusion, FS inhibited MCF-7 tumor growth in a dose-dependent manner and enhanced the inhibitory effect of TAM due to the modulation of ER and growth factor signal transduction pathways.
Get full access to this article
View all access options for this article.
References
1.
Jordan VC. The past, present, and future of selective estrogen receptor modulation. Ann N Y Acad Sci949:72–79, 2001.
2.
Carrizosa DR, Carey LA. Adjuvant systemic therapy in young women. Breast Dis23:67–71, 2005.
3.
MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev50:151–196, 1998.
4.
Headley JA, Theriault RL, LeBlanc AD, Vassilopoulou-Sellin R, Hortobagyi GN. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest16:6–11, 1998.
5.
Shapiro CL, J. Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol19:3306–3311, 2001.
6.
Eisenberg DM, Davis RB, Ettner SL. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA280:1569–1575, 1998.
7.
Vande Creek L, Rogers E, Lester J. Use of alternative therapies among breast cancer outpatients compared with the general population. Alter Ther Health Med5: 71–76, 1999.
8.
Weiger WA, Smith M, Boon H, Richardson MA, Kaptchuk TJ, Eisenber DM. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med137:889–903, 2002.
9.
Boon HS, Olatunde F, Zick. Trends in complementary/alternative medicine use by breast cancer survivors: Comparing survey data from 1998 and 2005. BMC Women’s Health7:4, 2007.
10.
Gardiner P, Legedza A, Woods C, Phillips RS, Kemper KJ. Herb use among health care professionals enrolled in an online curriculum on herbs and dietary supplements. J Herb Pharmacother6:51–64, 2006.
11.
Thompson LU, Seidl MM, Richard SE, Orcheson LJ, Fong HH. Antitumorigenic effect of a mammalian lignan precursor from flaxseed. Nutr Cancer26:159–165, 1996.
12.
Thompson LU. Flaxseed, lignans, and cancer. In: Thompson LU, Cunnane SC, Eds. Flaxseed in Human Nutrition (2nd ed). Champaign: AOCS Press, pp194–222, 2003.
13.
Bougnoux P, Chajes V. α-Linolenic acid and cancer. In: Thompson LU, Cunnane SC, Eds. Flaxseed in Human Nutrition (2nd ed). Champaign: AOCS Press, pp232–244, 2003.
14.
Mueller SO, Simon S, Chae K, Metzler M, Korach KS. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci2004;80:14–25.
15.
Chen J, Hui E, Ip T, Thompson LU. Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice. Clin Cancer Res10:7703–7711, 2004.
16.
Chen J, Stavro PM, Thompson LU. Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutr Cancer43:187–192, 2002.
17.
Dabrosin C, Chen J, Wang L, Thompson LU. Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts. Cancer Lett185:31–37, 2002.
18.
Thompson LU, Chen JM, Li T, Strasser-Weippl K, Goss PE. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res11:3828–3835, 2005.
19.
Olfer ED, Cross BM, McWilliam AA, Eds. The Guide to the Care and Use of Experimental Animals, Vol 1 (2nd ed). Ottawa: Canadian Council on Animal Care, 1993.
20.
Reeves PG, Nielsen FH, Fahey Jr GC. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr123:1939–1951, 1993.
21.
Thompson LU, Rickard SE, Orcheson LJ, Seidl MM. Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. Carcinogenesis17:1373–1376, 1996.
22.
Rickard SE, Yuan YV, Chen J, Thompson LU. Dose effects of flaxseed and its lignan on N-methyl-N-nitrosourea-induced mammary tumorigenesis in rats. Nutr Cancer35:50–57, 1999.
23.
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol11:155–168, 1998.
24.
Wang C, Kurzer MS. Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr Cancer28:236–247, 1997
25.
Mousavi Y, Adlercreutz H. Enterolactone and estradiol inhibit each other’s proliferative effect on MCF-7 breast cancer cells in culture. J Steroid Biochem Mol Biol41:615–619, 1992.
26.
Welshons WV, Murphy CS, Koch R, Calaf G, Jordan VC. Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and the phytoestrogen equol. Breast Cancer Res Treat10:169–175, 1987.
27.
Saarinen NM, Penttinen PE, Smeds AI, Hurmerinta TT, Makela SI. Structural determinants of plant lignans for growth of mammary tumors and hormonal responses in vivo. J Steroid Biochem Mol Biol93:209–219. 2005.
28.
Saarinen NM, Huovinen R, Warri A, Makela SI, Valentin-Blasini L, Sjoholm R, Ammala J, Lehtila R, Eckerman C, Collan YU, Santti RS. Enterolactone inhibits the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in the rat. Mol Cancer Ther1:869–876, 2002.
29.
Saarinen NM, Huovinen R, Warri A, Makela SI, Valentin-Blasini L, Needham L, Eckerman C, Collan YU, Santti R. Uptake and metabolism of hydroxymatairesinol in relation to its anticarcinogenicity in DMBA-induced rat mammary carcinoma model. Nutr Cancer41:82–90, 2001.
30.
Saarinen NM, Power K, Chen J, Thompson LU. Flaxseed attenuates the tumor growth stimulating effect of soy protein in ovariectomized athymic mice with MCF-7 human breast cancer xenografts. Int J Cancer119:925–931, 2006.
31.
Power KA, Saarinen NM, Chen JM, Thompson LU. Mammalian lignans enterolactone and enterodiol, alone and in combination with the isoflavone genistein, do not promote the growth of MCF-7 xenografts in ovariectomized athymic nude mice. Int J Cancer118:1316–1320, 2006.
32.
Jungerstrom MB, Thompson LU, Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of VEGF in human breast cancer xenografts in vivo. Clin Cancer Res13:1061–1067, 2007.
33.
Pink JJ, Jordan VC. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res56: 2321–2330, 1996.
34.
Arafah BM, Finegan HM, Roe J, Manni A, Pearson OH. Hormone dependency in N-nitrosomethylurea-induced rat mammary tumors. Endocrinology111:584–588, 1982.
35.
Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol21:1973–1979, 2003.
36.
Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol19:833–842, 2005.
37.
Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer12:S99–S111, 2005.
38.
Detre S, Riddler S, Salter J, A’Hern R, Dowsett M, Johnston SR. Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model. Cancer Res63:6516–6522, 2003.
39.
Rickard SE, Yuan YV, Thompson LU. Plasma insulin-like growth factor I levels in rats are reduced by dietary supplementation of flaxseed or its lignan secoisolariciresinol diglycoside. Cancer Lett161:47–55, 2000.
40.
Chong YM, Colston K, Jiang WG, Sharma AK, Mokbel K. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue. Breast Cancer Res Treat99:275–288, 2006.
41.
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet351: 1393–1396, 1998.
42.
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen activated protein kinase. Science270:1491–1494, 1995.
43.
Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science277:1508–1510, 1997.
44.
Garvin S, Dabrosin C. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res63: 8742–8748, 2003.
45.
Stoll BA. n-3 fatty acids and lipid peroxidation in breast cancer inhibition. Br J Nutr87:193–198, 2002.
46.
Rose DP. Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies. Am J Clin Nutr66:1513S–1522S, 1997.
47.
Rose DP. Dietary fatty acids and prevention of hormone-responsive cancer. Proc Soc Exp Biol Med216:224–233, 1997.
48.
El-Sohemy A, Archer MC. Regulation of mevalonate synthesis in rat mammary glands by dietary n-3 and n-6 polyunsaturated fatty acids. Cancer Res57:3685–3687, 1997.
49.
DeGraffenried LA, Friedrichs WE, Fulcher L, Fernandes G, Silva JM, Peralba JM, Hidalgo M. Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity. Ann Oncol14: 1051–1056, 2003.
50.
Liu Z, Saarinen NM, Thompson LU. Sesamin is one of the major precursors of mammalian lignans in sesame seed (Sesamum indicum) as observed in vitro and in rats. J Nutr136:906–912, 2006.
51.
Sacco SM, Power KA, Chen J, Ward WE, Thompson LU. Interaction of sesame seed and tamoxifen on tumor growth and bone health in athymic mice. Exp Biol Med (Maywood)232:754–761, 2007.
52.
Power KA, Ward WE, Chen JM, Saarinen NM, Thompson LU. Flaxseed and soy protein isolate, alone and in combination, differ in their effect on bone mass, biomechanical strength, and uterus in ovariectomized nude mice with MCF-7 human breast tumor xenografts. J Toxicol Environ Health A2007 (in press).
53.
Power KA, Ward WE, Chen JM, Saarinen NM, Thompson LU. Genistein alone and in combination with the mammalian lignans enterolactone and enterodiol induce estrogenic effects on bone and uterus in a postmenopausal breast cancer mouse model. Bone39:117–124, 2006.
54.
Chen J, Wang L, Thompson LU. Flaxseed and its components reduce metastasis after surgical excision of solid human breast tumor in nude mice. Cancer Lett234:168–175, 2006.
55.
Angelova V, Ivanova R, Delibaltova V, Ivanov K. Bio-accumulation and distribution of heavy metals in fibre crops (flax, cotton and hemp). Ind Corps Prod19:197–205, 2004.
56.
Hocking PJ, McLaughlin MJ. Genotypic variation in cadmium accumulation by seed of linseed, and comparison with seed of some other crop species. Austr J Agric Res52:427–433, 2006.
57.
Johnson MD, Kenney N, Stoica A, Hilakivi-Clarke L, Singh B, Chepko G, Clarke R, Sholler PF, Lirio AA, Foss C, Reiter R, Trock B, Paik S, Martin MB. Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland, Nat Med9:1081–1084, 2003.
